Ivabradine Treatment in a Chronic Heart Failure Patient Cohort: Symptom Reduction and Improvement in Quality of Life in Clinical Practice

Advances in Therapy

Volumn 31, Issue 9, 2014, Pages 961-974

  Zugck, Christian ^a   Martinka, Peter ^b   Stöckl, Georg ^b  

^a Clinic Group Practice for Internal Medicine   (Germany)

^b Servier Deutschland GmbH   (Germany)

Author keywords

Cardiology; Chronic heart failure; Heart rate; Ivabradine; NYHA class; Quality of life; Symptom reduction

Indexed keywords

ACETYLSALICYLIC ACID; ALDOSTERONE ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; BRAIN NATRIURETIC PEPTIDE; CARDIAC GLYCOSIDE; CARVEDILOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IVABRADINE; METOPROLOL; NEBIVOLOL; BENZAZEPINE DERIVATIVE; CARDIOVASCULAR AGENT;

AGED; ARTICLE; BRADYCARDIA; CLINICAL PRACTICE; CONTROLLED STUDY; DRUG EFFICACY; DRUG TOLERABILITY; EYE DISEASE; FEMALE; FOLLOW UP; HEART DISEASE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEUROLOGIC DISEASE; QUALITY OF LIFE; RESTING HEART RATE; SYMPTOM ASSESSMENT; SYSTOLIC HEART FAILURE; VERY ELDERLY; BLOOD; CHRONIC DISEASE; CLINICAL TRIAL; DRUG COMBINATION; HEART FAILURE; HEART RATE; MIDDLE AGED; PROSPECTIVE STUDY; TREATMENT OUTCOME;

ADRENERGIC BETA-ANTAGONISTS; AGED; AGED, 80 AND OVER; ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BENZAZEPINES; CARDIOVASCULAR AGENTS; CHRONIC DISEASE; DIURETICS; DRUG THERAPY, COMBINATION; FEMALE; HEART FAILURE; HEART RATE; HUMANS; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PROSPECTIVE STUDIES; QUALITY OF LIFE; TREATMENT OUTCOME;

EID: 84919708023     PISSN: 0741238X     EISSN: 18658652     Source Type: Journal    
DOI: 10.1007/s12325-014-0147-3     Document Type: Article

References (27)

1. Pocock SJ, Wang D, Pfeffer MA, et al. Predictors of mortality and morbidity in patients with chronic heart failure. Eur Heart J. 2006;27:65–75.
2. Böhm M, Swedberg K, Komajda M, et al. Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial. Lancet. 2010;376:886–94.
3. Fox K, Ford I, Steg PG, et al. Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trial. Lancet. 2008;372:817–21.
4. Reil JC, Custodis F, Swedberg K, et al. Heart rate reduction in cardiovascular disease and therapy. Clin Res Cardiol. 2011;100(1):11–9.
5. Lonn EM, Rambihar S, Gao P, et al. Heart rate is associated with increased risk of major cardiovascular events, cardiovascular and all-cause death in patients with stable chronic cardiovascular disease: an analysis of ONTARGET/TRANSCEND. Clin Res Cardiol. 2014;103:149–59.
6. Foody JM, Farrell MH, Krumholz HM. Beta-blocker therapy in heart failure: scientific review. JAMA. 2002;287(7):883–9.
7. McMurray J, Adamopoulos S, Anker SD, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012. Eur Heart J. 2012;33:1787–847.
8. Franke J, Wolter JS, Meme L, et al. Optimization of pharmacotherapy in chronic heart failure: is heart rate adequately addressed? Clin Res Cardiol. 2013;102(1):23–31.
9. Maggioni AP, Anker SD, Dahlström U, et al. Are hospitalized or ambulatory patients with heart failure treated in accordance with European Society of Cardiology guidelines? Evidence from 12,440 patients of the ESC heart failure long-term registry. Eur J Heart Fail. 2013;15(10):1173–84.
10. Tardif JC, Ford I, Tendera M, et al. Efficacy of ivabradine, a new selective I(f) inhibitor, compared with atenolol in patients with chronic stable angina. Eur Heart J. 2005;26(23):2529–36.
11. Ruzyllo W, Tendera M, Ford I, Fox KM. Antianginal efficacy and safety of ivabradine compared with amlodipine in patients with stable effort angina pectoris: a 3-month randomized, double-blind, multicenter, non-inferiority study. Drugs. 2007;67(3):393–405.
12. Swedberg K, Komajda M, Böhm M, et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet. 2010;376:875–85.
13. Böhm M, Borer J, Ford I, et al. Heart rate at baseline influences the effect of ivabradine on cardiovascular outcomes in chronic heart failure: analyses from the SHIFT study. Clin Res Cardiol. 2013;102(1):11–22.
14. Sargento L, Satendra M, Longo S, et al. Early NT-porBNP decrease with ivabradine in ambulatory patients with systolic heart failure. Clin Cardiol. 2013;36(11):677–82.
15. Volterrani M, Cice G, Caminiti G, et al. Effect of carvedilol, ivabradine or their combination on exercise capacity in patients with heart failure (the CARVIVA HF trial). Int J Cardiol. 2011;151(2):218–24.
16. Wikstrand J, Hjalmarson A, Waagstein F, et al. Dose of metoprolol CR/XL and clinical outcomes in patients with heart failure. JACC. 2002;40(3):491–8.
17. Swedberg K, Komajda M, Böhm M, et al. Effects on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure: is there an influence of beta-blocker dose? Findings from the SHIFT (systolic heart failure treatment with the I(f) inhibitor ivabradine trial) study. J Am Coll Cardiol. 2012;59(22):1938–45.
18. Cullington D, Goode KM, Clark AL, et al. Heart rate achieved or beta-blocker dose in patients with chronic heart failure: which is the better target? Eur J Heart Fail. 2012;14(7):737–47.
19. Flannery G, Gehrig-Mills R, Billah B, et al. Analysis of randomized controlled trials on the effect of magnitude of heart rate reduction on clinical outcomes in patients with systolic chronic heart failure receiving beta-blockers. Am J Cardiol. 2008;101(6):865–9.
20. McAlister FA, Wiebe N, Ezekowitz JA, et al. Meta-analysis: beta-blocker dose, heart rate reduction, and death in patients with heart failure. Ann Intern Med. 2009;150:784–94.
21. Ekman I, Chassany O, Komajda M, et al. Heart rate reduction with ivabradine and health related quality of life in patients with chronic heart failure: results from the SHIFT study. Eur Heart J. 2011;32:2395–404.
22. Denvir MA, Lee AJ, Rysdale J, et al. Influence of socioeconomic status on clinical outcomes and quality of life after percutaneous coronary intervention. J Epidemiol Community Health. 2006;60:1085–8.
23. Werdan K, Ebelt H, Nuding S, et al. Ivabradine in combination with beta-blocker improves symptoms and quality of life in patients with stable angina pectoris: results from the ADDITIONS study. Clin Res Cardiol. 2012;101(5):365–73.
24. Dobre D, van Jaarsveld C, deJongste M, et al. The effect of beta-blocker therapy on quality of life in heart failure patients: a systematic review and meta-analysis. Pharmacoepidemiol Drug Saf. 2007;16(2):152–9.
25. Riccioni G, Masciocco L, Benvenuto A, et al. Ivabradine improves quality of life in subjects with chronic heart failure compared to treatment with β-blockers: results of a multicentric observational APULIA study. Pharmacology. 2013;92(5–6):276–80.
26. Dobre D, de Jongste MJ, Haaijer-Ruskamp FM, et al. The enigma of quality of life in patients with heart failure. Int J Cardiol. 2008;125(3):407–9.
27. Udelson JE, Feldman AM, Greenberg B, et al. Randomized, double-blind, multicenter, placebo-controlled study evaluating the effect of aldosterone antagonism with eplerenone on ventricular remodeling in patients with mild-to-moderate heart failure and left ventricular systolic dysfunction. Circ Heart Fail. 2010;3(3):347–53.